Chromosomal Damage in Type 2 Diabetes Patients (MIKRODIAB) (MIKRODIAB)
Incidence of Chromosomal Damage in Type 2 Diabetes Patients
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Karl-Heinz Wagner, PhD
- Phone Number: 00431427754930
- Email: Karl-Heinz.wagner@univie.ac.at
Study Contact Backup
- Name: Annemarie Grindel
- Phone Number: 00431427754901
- Email: annemarie.grindel@univie.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- University of Vienna
-
Contact:
- Karl-Heinz Wagner, PhD
- Phone Number: 54930 004314277
- Email: Karl-Heinz.wagner@univie.ac.at
-
Contact:
- Annemarie Grindel
- Phone Number: 54901 004314277
- Email: annemarie.grindel@univie.ac.at
-
Sub-Investigator:
- Helmuth Brath, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Type 2 Diabetes (T2DM)
- Sex: female
- Age: > 30years
- Medication: oral anti-diabetics and/or Insulin therapy
- Constant nutritional behavior, constant physical activity, constant weight for the last 4 weeks
- Non-smoking for at least 1 year
Exclusion Criteria:
- Patients with type 1 DM
- Age: < 30years
- Pregnant or lactating women
- Participation in another clinical trial
- Change of medication in regard to metabolic parameters within the last 4 weeks
- Significant cardiovascular damage with NYHA > III
- Liver disease with three-times higher transaminase values
- Chronic kidney disease with serum creatinine > 2 mg/dl
- Dialysis
- HIV positive
- History of chronic alcohol abuse in the last two years
- History of cancer, stroke, organ transplantation
- Male
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Type 2 diabetes, HbA1c>7.5
|
|
Type 2 diabetes, HbA1c<7.5
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The quality of HbA1c influences micronuclei formation in binucleated cells
Time Frame: Baseline
|
In this cross-sectional study the micronuclei formation in binucleated lymphocytes (Number of micronuclei/1000 binucleated cells) is compared between a low (HbA1c<7.5%)
and a high (HbA1c>7.5%)
glycemic group
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Type 2 diabetes duration of the subjects influences chromosomal damage
Time Frame: Baseline
|
The micronuclei formation in binucleated lymphocytes (Number of micronuclei/1000 binucleated cells) is associated with the duration of the Typ 2 diabetes disease.
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Karl-Heinz Wagner, PhD, UNIVIE
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UNIVIE-549-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.